An exciting development in cancer diagnostics is here. HER2, pan-tumor immunohistochemistry testing allows more patients to potentially access effective antibody-drug conjugate (ADC) therapies such as Enhertu, which is the first tumor-agnostic ADC approved in oncology. Learn more: http://spr.ly/6042QiBee
Labcorp’s Post
More Relevant Posts
-
🔬 Insights from ASCO 2024! Dr Antonio Marra from the European Institute of Oncology discusses cyclin-E1 amplification in advanced breast cancer. This subset of patients shows poor outcomes with standard therapies but promising responses with PKMYT1 and CDK-2 inhibitors in preclinical models. Learn about the potential for new targeted treatments. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #BreastCancer #OncologyInnovation #CyclinE1
-
Excellent analysis in an increasingly relevant and important field.
Most viewed in the last 7 days from JAMA Oncology: Are androgen receptor signaling inhibitors associated with increased risk of CV events in men with advanced and metastatic prostate cancer? https://ja.ma/4coNvGZ
-
-
Completed my post graduation in Medical Oncology from Bangabandhu Sheikh Muzib Medical University,Dhaka on 2021 and currently working at Kurmitola General Hospital
We should consider KN 826 in our regular practice. Specially after the final analysis
Pembrolizumab Plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study. Now out in annals of oncology
-
-
Numerous studies have shown that stress can not only contribute to cancer initiation and impair treatment effectiveness but can also promote cancer growth and the development of metastases[1]. To achieve better overall outcomes in oncology, it is imperative to identify additional sources of stress in cancer patients and address them effectively. To read the article, click here: https://lnkd.in/g5spe4Bf
-
-
Numerous studies have shown that stress can not only contribute to cancer initiation and impair treatment effectiveness but can also promote cancer growth and the development of metastases[1]. To achieve better overall outcomes in oncology, it is imperative to identify additional sources of stress in cancer patients and address them effectively. To read the article, click here: https://lnkd.in/epZeUqj4
-
-
Numerous studies have shown that stress can not only contribute to cancer initiation and impair treatment effectiveness but can also promote cancer growth and the development of metastases[1]. To achieve better overall outcomes in oncology, it is imperative to identify additional sources of stress in cancer patients and address them effectively. To read the article, click here: https://lnkd.in/eqrRkCVm
-
-
The Oncolines® team want to take a moment to share with you an article that provides insight in their work. We READcommend our article in Frontiers in Oncology on cell panel profiling and biochemical profiling of kinase inhibitors. A must-read for anyone passionate about advancing cancer research and targeted therapies. Check it out here: https://lnkd.in/eyVA8GEe #CancerResearch #Oncolines #READcommendation
-
-
Numerous studies have shown that stress can not only contribute to cancer initiation and impair treatment effectiveness but can also promote cancer growth and the development of metastases[1]. To achieve better overall outcomes in oncology, it is imperative to identify additional sources of stress in cancer patients and address them effectively. To read the article, click here: https://lnkd.in/d4a4Nfrf
-
-
Another important publication demonstrating Fortrea's leadership across oncology clinical development. Breast cancer is a leading cause of mortality and morbidity worldwide. This article reviews the current landscape of neoadjuvant therapy for HR+/HER2- breast cancer, focusing on #biomarkers for decision making, and exploring next steps of #clinicalresearch in this therapeutic space. #oncologyclinicaltrials
